EatonWTharaRFedermanE. Remission and relapse in schizophrenia: the Madras longitudinal study. J Nerv Ment Dis1998; 186: 357–363.
2.
ChouinardGJonesBD.Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry1980; 137: 16–21.
3.
LambertTJ.Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry2007; 68: 10–13.
4.
SamahaANSeemanPStewartJ. Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci2007; 27: 2979–2986.
5.
SeemanP.Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizoph Relat Psychoses2010; 4: 56–73.
6.
StipETourjmanVLewV. “Awakenings” effect with risperidone. AMJ Psychiatry1995; 152: 1833.
7.
GotoSTeraoTTomitaM. Aripiprazole may be free from tachyphylaxis: preliminary findings. Psychiatry Clin Neurosci 2012; 66:160–162.
8.
YaminSVaddadiK.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int Rev Psychiatry2010; 22: 138–147.
9.
HoBCAndreasenNCZiebellS. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry2010; 68: 128–137.
